Johannes Vermehren
Overview
Explore the profile of Johannes Vermehren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dietz J, Graf C, Berg C, Port K, Deterding K, Buggisch P, et al.
JHEP Rep
. 2024 Jul;
6(7):101072.
PMID: 39006503
Background And Aims: Data on the prevalence and characteristics of so-called rare HCV genotypes (GTs) in larger cohorts is limited. This study investigates the frequency of rare GT and resistance-associated...
2.
Krassenburg L, Maan R, Puenpatom A, Erler N, Welsch C, van Hees S, et al.
BMJ Open Gastroenterol
. 2024 Apr;
10(1).
PMID: 38637963
Background And Aims: Historical paired liver biopsy studies are likely to underestimate current progression of disease in patients with chronic hepatitis C virus (HCV) infection. We aimed to assess liver...
3.
Graf C, DAmbrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J, et al.
JHEP Rep
. 2024 Feb;
6(3):100994.
PMID: 38357421
Background & Aims: Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection. In the present study, predictors of virologic treatment response were analyzed...
4.
Mucke V, Fischer J, Mucke M, Teumer A, Koch A, Vermehren J, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36615054
(1) Background: The inherited alpha-1 antitrypsin (A1AT) deficiency variant 'Pi*Z' emerged as a genetic modifier of chronic liver disease. Controversial data exist on the relevance of heterozygous Pi*Z carriage ('Pi*MZ'...
5.
Graf C, Arncken J, Lange C, Willuweit K, Schattenberg J, Seessle J, et al.
JHEP Rep
. 2021 Nov;
3(6):100360.
PMID: 34765958
Background & Aims: Clinical manifestation of hepatic involvement in sarcoidosis can vary from asymptomatic disease to severe complications such as cirrhosis and portal hypertension. However, data on hepatic sarcoidosis are...
6.
Knop V, Hoppe D, Vermehren J, Troetschler S, Herrmann E, Vermehren A, et al.
J Viral Hepat
. 2021 Aug;
28(11):1604-1613.
PMID: 34342081
Long-term effects on cirrhosis and portal hypertension of direct antiviral agent (DAA)-based eradication of hepatitis C virus (HCV) are still under debate. We analysed dynamics of liver and spleen elastography...
7.
Wilde A, Lieb C, Leicht E, Greverath L, Steinhagen L, de Chamorro N, et al.
J Clin Med
. 2021 Apr;
10(5).
PMID: 33806503
Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12...
8.
Hernandez Sampere L, Vermehren J, Mucke V, Graf C, Peiffer K, Dultz G, et al.
Hepatol Commun
. 2021 Jan;
5(1):112-121.
PMID: 33437905
Chronic viral hepatitis is associated with substantial morbidity and mortality worldwide. The aim of our study was to assess the ability of point shear-wave elastography (pSWE) using acoustic radiation force...
9.
Dietz J, Di Maio V, De Salazar A, Merino D, Vermehren J, Paolucci S, et al.
J Hepatol
. 2020 Nov;
74(4):801-810.
PMID: 33220331
Background & Aims: There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment...
10.
Peiffer K, Spengler C, Basic M, Jiang B, Kuhnhenn L, Obermann W, et al.
JCI Insight
. 2020 Oct;
5(22).
PMID: 33055418
Many mutation analyses of the HBV genome have been performed in the search for new prognostic markers. However, the Kozak sequence preceding precore was covered only infrequently in these analyses....